FIELD: chemistry.
SUBSTANCE: invention relates to organic chemistry and specifically to novel heterocyclic compounds of formula I or pharmaceutically acceptable salts thereof, where R1 is selected from a group consisting of hydrogen and C1-C6-alkyl; where C1-C6-alkyl is optionally substituted with one substitute independently selected from halogen, hydroxy or C1-C3-alkoxy; R2 is C1-C3-alkyl; is 0 or 1; R3 is selected from a group consisting of hydroxy, C1-C6-alkyl and C1-C6-alkoxy, where each of C1-C6-alkyl and C1-C6-alkoxy is optionally substituted with 2–3 fluorine atoms; R4 is hydrogen; A is selected from a group consisting of phenyl and 6-member heteroaryl, 1 or 2 ring atoms in 6-member heteroaryl are nitrogen and the remaining ring atoms are carbon; and where phenyl and 6-member heteroaryl are optionally substituted with 1 R6; R5 is selected from a group consisting of halogen, C1-C6-alkyl, C1-C6-alkoxy, C1-C6-alkoxy-C1-C6-alkyl, C3-C7-cycloalkyl, C3-C7-cycloalkyl-C1-C6-alkyl, C3-C7-cycloalkoxy, phenoxy, 4–6-member heterocycloalkyl and 5–6-member heterocycloalkoxy, where 1 ring atom in heterocycloalkyl and heterocycloalkoxy is oxygen, and the remaining ring atoms are carbon; where C1-C6-alkyl, C1-C6-alkoxy and C1-C6-alkoxy-C1-C6-alkyl is optionally substituted with one or two substitutes independently selected from halogen or hydroxy; and where C3-C7-cycloalkyl, C3-C7-cycloalkyl-C1-C6-alkyl, C3-C7-cycloalkoxy, phenoxy, 4–10-member heterocycloalkyl and 4–10-member heterocycloalkoxy are optionally substituted with one to two R7; R6 is selected from a group consisting of halogen, and C1-C6-alkyl; or R5 and R6, when they are bonded to adjacent carbon atoms and taken together with adjacent carbon atoms to which they are bonded, form a condensed tetrahydropyrine or tetrahydrofuran ring which is optionally substituted with one or two R8; R7 in each case is independently selected from a group consisting of halogen, hydroxy, C1-C3-alkyl optionally substituted with three fluorine atoms or C1-C3-alkoxy, and C1-C3-alkoxy, optionally substituted with one fluorine atom; and R8 in each case is C1-C3-alkyl. Also disclosed are specific compounds of formula (I), a pharmaceutical composition based on the compound of formula (I) and use of the compound of formula (I) as a D3 receptor modulator.
I
EFFECT: technical result is obtaining novel pyrido[2,3-d]azepine derivatives useful for treating a disease mediated by D3 receptors.
29 cl, 8 tbl, 15 ex
| Title | Year | Author | Number |
|---|---|---|---|
| 4-HYDROXYBENZOPYRAN-2-ONE OR 4-HYDROXYCYCLOALKYL[B]BENZOPYRAN- -2-ONE AND, METHOD OF SYNTHESIS OF N-[3-[CYCLOPROPYL- -(5,6,7,8,9,10-HEXAHYDRO-4-HYDROXY-2-OXO-2H-CYCLOOCTA[B]- -PYRAN-3-YL)METHYL]PHENYL]-BENZENESULFONE | 1994 |
|
RU2125999C1 |
| DERIVATIVES OF BENZENESULPHONAMIDES AS INVERSE AGONISTS ASSOCIATED WITH RETINOIDS ROR ORPHAN GAMMA RECEPTOR (T) | 2015 |
|
RU2724331C2 |
| NEW TETRAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF TUBERCULOSIS | 2018 |
|
RU2800930C2 |
| MKK4 PROTEIN KINASE INHIBITORS FOR STIMULATION OF LIVER REGENERATION OR REDUCTION OR PREVENTION OF HEPATOCYTE DEATH | 2019 |
|
RU2788000C2 |
| PYRAZOLE DERIVATIVES APPLIED AS PROTEIN KINASE INHIBITORS | 2013 |
|
RU2623221C2 |
| PYRIDONE DERIVATIVE HAVING TETRAHYDROPYRANYLMETHYL GROUP | 2015 |
|
RU2707953C2 |
| SOLID DISPERSIONS PRODUCED BY MELT EXTRUSION AND CONTAINING APOPTOSIS-INDUCING AGENT | 2011 |
|
RU2577859C2 |
| APOPTOSIS-INDUCING AGENTS FOR TREATING MALIGNANT TUMOURS AND IMMUNE AND AUTOIMMUNE DISEASES | 2010 |
|
RU2573832C2 |
| TRICYCLIC COMPOUNDS OF BENZOPYRAN AS ANTIARRHYTHMIC AGENTS | 2005 |
|
RU2380370C2 |
| SOLID DISPERSIONS CONTAINING AGENTS CAUSING APOPTOSIS | 2011 |
|
RU2598345C2 |
